Current Research Studies

A two-stage double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with a PIK3CA mutation

EPIK-L1

Condition(s): Other
Phase: II/III
Clinicaltrials.gov ID: NCT04589650

What is the goal of the study?

To demonstrate the efficacy and safety and assess pharmacokinetics of alpelisib in participants with lymphatic malformations associated with a PIK3CA mutation.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Jonathan Perkins
Study Team Member: Dhanashree Sawant, Dhanashree.Sawant@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.